Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma (VOR) insider filing reports open‑market sales by an affiliate of director Reid Hoffman totaling 96,657 shares across 10/10–10/14/2025, executed at weighted average prices disclosed in the filing. Following these transactions, 1,278,118 shares were beneficially owned.
The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his interest. The filing was made by more than one reporting person.
Amendment No. 6 to Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman jointly beneficially own 1,374,775 shares of Vor Biopharma Inc., representing
Vor Biopharma Inc. (VOR) insiders reported multiple open-market sales of common stock on
Amendment No. 5 to a Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 1,498,921 shares of Vor Biopharma Inc., representing 21.9% of the outstanding common stock. The amendment discloses open-market sales that reduced the Reporting Persons' stake by more than one percent: 70,763 shares sold on
Vor Biopharma Inc. reporting persons Reprogrammed Interchange LLC and Reid Hoffman disclosed multiple open-market sales of common stock on
The document clarifies that the reported prices are weighted averages from multiple trades and that Mr. Hoffman may be deemed an indirect beneficial owner of the shares held by Reprogrammed but disclaims ownership except for his pecuniary interest. Signatures for Reid Hoffman and Frank Huang (Manager of Reprogrammed Interchange LLC) appear with dates of
Reprogrammed Interchange LLC and Reid Hoffman filed Amendment No. 4 to a Schedule 13D reporting combined beneficial ownership of 1,597,308 shares, equal to
The filing lists discrete sales including 99,115 shares sold from
Vor Biopharma (VOR) reported insider sales on a Form 4 by Reprogrammed Interchange LLC, attributed to director Reid Hoffman. The transactions occurred on October 1–3, 2025 and were executed in multiple trades at weighted-average prices within a disclosed range of $36.82 to $42.70. Following the reported sales, the filing shows 1,597,308 shares beneficially owned, held directly. The share figures reflect a 1-for-20 reverse stock split effected on September 18, 2025. The filing notes Hoffman may be deemed a beneficial owner through shared control of Reprogrammed and disclaims ownership except to his pecuniary interest.
Verve Capital Limited reports beneficial ownership of 760,699 shares of Vor Biopharma Inc. common stock, representing a capped 9.99% ownership stake under the terms of pre-funded warrants. The reporting person directly holds pre-funded warrants exercisable for up to 2,000,000 shares but the warrants include a Beneficial Ownership Blocker that prevents exercise to the extent it would increase beneficial ownership above 9.99%. The reported percentage is calculated using 6,853,907 shares outstanding plus the 760,699 shares issuable upon exercise, and the EDGAR system rounding leads the cover page to show 9.9%.
The filing states Verve Capital has sole voting and dispositive power over the 760,699 shares and classifies the filer as a company organized in Samoa. The statement affirms the securities were not acquired to change control of the issuer.
Vor Biopharma Inc. has a group of reporting persons led by Venrock-related entities and two individuals that together beneficially own 760,699 shares of the company's common stock, representing a reported ownership position capped at 9.99% due to a pre-funded warrant provision. The filing discloses the composition of the holdings across multiple Venrock vehicles: VHCP III, VHCP Co-Investment III and VHCP EG, and explains that certain pre-funded warrants include a Beneficial Ownership Blocker that prevents exercise beyond the 9.99% threshold.
The percentage calculation references 6,853,907 shares outstanding as of September 18, 2025, plus subsequent issuances and exercisable amounts used to determine the 9.99% figure; EDGAR field limits caused cover-page percentages to be shown as 9.9%. The reporting group lists shared voting and dispositive power of 760,699 shares and provides powers of attorney and a joint filing agreement as exhibits.
Vor Biopharma Inc. filed an S-8 registration to register an additional 8,761,334 shares of common stock for its employee benefit plans. The filing incorporates by reference prior S-8 filings and periodic reports including the annual report for the fiscal year ended December 31, 2024 and 10-Qs for March 31, 2025 and June 30, 2025. A schedule of exhibits lists charter and bylaw amendments, equity plans, legal opinion and auditor consents.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
